---
figid: PMC6858516__nihms-1054030-f0006
figlink: /pmc/articles/PMC6858516/figure/F6/
number: Fig. 6 |
caption: Lineage plasticity has been increasingly observed in patients with metastatic
  castration-resistant prostate cancer (mCRPC) treated with androgen receptor pathway
  inhibitors (ARPIs) to drive prostate cancer from an adenocarcinoma histology towards
  a neuroendocrine prostate cancer (NEPC) phenotype. This change is associated with
  loss of androgen receptor (AR) expression, combined loss of RB1 and TP53, and distinct
  epigenetic changes. In preclinical studies, inhibition of the epigenetic regulator
  EZH2 has a potential role in reversing the phenotype back towards an AR+ adenocarcinoma
  to regain responses to enzalutamide (ENZ). adeno, adenocarcinoma; EZH2i, EZH2 inhibition;
  tNEPC, treatment-related NEPC.
pmcid: PMC6858516
papertitle: Towards precision oncology in advanced prostate cancer.
reftext: Sheng-Yu Ku, et al. Nat Rev Urol. ;16(11):645-654.
pmc_ranked_result_index: '68249'
pathway_score: 0.9465076
filename: nihms-1054030-f0006.jpg
figtitle: Towards precision oncology in advanced prostate cancer
year: ''
organisms: Homo sapiens
ndex: 1051244c-dea3-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6858516__nihms-1054030-f0006.html
  '@type': Dataset
  description: Lineage plasticity has been increasingly observed in patients with
    metastatic castration-resistant prostate cancer (mCRPC) treated with androgen
    receptor pathway inhibitors (ARPIs) to drive prostate cancer from an adenocarcinoma
    histology towards a neuroendocrine prostate cancer (NEPC) phenotype. This change
    is associated with loss of androgen receptor (AR) expression, combined loss of
    RB1 and TP53, and distinct epigenetic changes. In preclinical studies, inhibition
    of the epigenetic regulator EZH2 has a potential role in reversing the phenotype
    back towards an AR+ adenocarcinoma to regain responses to enzalutamide (ENZ).
    adeno, adenocarcinoma; EZH2i, EZH2 inhibition; tNEPC, treatment-related NEPC.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AR
  - AURKA
  - E2F7
  - E2F1
  - E2F2
  - E2F3
  - E2F4
  - E2F5
  - E2F6
  - E2F8
  - EZH2
  - MYCN
  - RB1
  - SOX2
genes:
- word: AR
  symbol: AR
  source: hgnc_symbol
  hgnc_symbol: AR
  entrez: '367'
- word: AURKA
  symbol: AURKA
  source: hgnc_symbol
  hgnc_symbol: AURKA
  entrez: '6790'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F7
  entrez: '144455'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F1
  entrez: '1869'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F2
  entrez: '1870'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F3
  entrez: '1871'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F4
  entrez: '1874'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F5
  entrez: '1875'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F6
  entrez: '1876'
- word: E2F
  symbol: E2F
  source: bioentities_symbol
  hgnc_symbol: E2F8
  entrez: '79733'
- word: EZH2
  symbol: EZH2
  source: hgnc_symbol
  hgnc_symbol: EZH2
  entrez: '2146'
- word: (N-MYC)
  symbol: N-myc
  source: hgnc_alias_symbol
  hgnc_symbol: MYCN
  entrez: '4613'
- word: RB1
  symbol: RB1
  source: hgnc_symbol
  hgnc_symbol: RB1
  entrez: '5925'
- word: SOX2
  symbol: SOX2
  source: hgnc_symbol
  hgnc_symbol: SOX2
  entrez: '6657'
chemicals: []
diseases: []
---
